Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Ischemia Stories

2011-12-06 06:00:00

PORTOLA VALLEY, Calif., Dec. 6, 2011 /PRNewswire/ -- Spectros Corporation announced today an expansion of its distribution channels in the Middle East with the signing of distributors based in the UAE, with expansion to other areas of the Middle East under discussion. These groups will join other distributors already selling Spectros products outside of the U.S. "We are excited by this continued expansion," noted Director of Sales Elizabeth van Thillo-Rohlff. "More and more physicians are...

2011-12-01 01:12:17

The ambivalent role of the CXCL12/ CXCR4 axis in heart repair The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the...

Damage From Heart Attack Dependent On Time Of Day
2011-11-22 06:20:41

In a first of its kind study, researchers have discovered  that the size of a heart attack and the remaining left-ventricular function that follows depends on the time of day that ischemia in the heart occurs. They found the greatest amount of damage happens when a heart attack occurs between 1:00 am and 5:00 am. Researchers had previously discovered that the amount of tissue death and the return of the blood supply to the heart exhibited a circadian dependence in rats. It was unknown...

2011-11-18 02:52:23

Reducing a protein called Siah2 in mice improves mitochondrial response to low oxygen, a condition cells experience when blood flow is restricted during a heart attack Mitochondria are often called cellular "powerhouses" because they convert nutrients into energy. But these tiny structures also help determine cellular lifespan. Scientists at Sanford-Burnham Medical Research Institute (Sanford-Burnham) are now discovering how mitochondria alternate between duplicating and fragmenting and...

2011-10-13 07:03:00

MOUNTAIN LAKES, N.J., Oct. 13, 2011 /PRNewswire/ -- Ferrer Therapeutics, the U.S. subsidiary of international pharmaceutical group, Ferrer Grupo, is introducing CerAxon® Oral Solution to the U.S. market, the first and only oral solution medical food containing citicoline. Taken for the dietary management of brain ischemia due to stroke or traumatic brain injury (TBI), CerAxon® Oral Solution provides patients who have difficulty swallowing with elevated...

2011-10-11 13:46:48

Bypassing the occlusion Mazzone has demonstrated that arteriogenesis (growth of pre-existing connections between distinct blood vessels into functional arteries) can be accelerated by blocking the function of the protein PhD2 in a particular class of white blood cells. This resulted in wider and functional vessels, which allows the blood to bypass the occlusion and thus offers better blood perfusion. The scientists want to investigate in further detail the therapeutic potential of blocking...

2011-09-08 07:00:00

ABBOTT PARK, Ill., Sept. 8, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the initiation of ABSORB BTK, an international clinical trial evaluating the safety and efficacy of the ABSORB(TM) bioresorbable vascular scaffold (BVS) for the treatment of below-the-knee (BTK) critical limb ischemia. Critical limb ischemia, a severe form of peripheral artery disease (PAD), occurs when blocked vessels impair blood flow to the lower extremities, which can eventually lead to limb amputation....

2011-09-08 06:00:00

MOUNTAIN VIEW, Calif., Sept. 8, 2011 /PRNewswire/ -- Concentric Medical, Inc., a global leader in acute ischemic stroke intervention, today announced completion of enrollment of the TREVO Study. The TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke) is the first evaluation of Stentriever(TM) technology in a European, multicenter, prospective clinical trial. The TREVO Study was designed to assess the ability of the Trevo®...

2011-09-06 06:00:00

MOUNTAIN VIEW, Calif., Sept. 6, 2011 /PRNewswire/ -- Concentric Medical, Inc. today announced the full European launch of Trevo® Pro 4 System. This next standard in Stentriever(TM) technology has an enhanced design to further promote clot integration across clot types in patients suffering an acute ischemic stroke. The Trevo® Pro 4 system is the next generation of Trevo Stentrievers from Concentric Medical and is used to remove thrombus in stroke...

2011-09-02 10:45:00

PORTOLA VALLEY, Calif., Sept. 2, 2011 /PRNewswire/ -- Spectros Corporation announced today an expansion of its distribution channels in Europe and Asia with the signing of 3 new distributors based in Korea, Switzerland, and Denmark. These groups join other distributors already selling Spectros products outside of the U.S. "We are excited that distributors are increasingly recognizing the opportunity offered by the superior performance of the T-Stat® 303 VLS Tissue...